Close Menu

NEW YORK (GenomeWeb) – Investment bank Barclays on Tuesday initiated coverage of the life science tools and diagnostics industry with the start of coverage on five firms and the upgrade of another company in the molecular diagnostics and omics tools space.

In a report, analyst Jack Meehan initiated coverage of Thermo Fisher Scientific and Myriad Genetics with Overweight ratings. He also gave Equal Weight ratings to Illumina and Agilent Technologies, and an Underweight rating to Hologic, while he upgraded Qiagen to an Overweight rating.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.